Insmed (INSM) Competitors

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership, community ranking and profitability.

Do insiders and institutionals hold more shares of RARE or INSM?

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 6.8% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 4.6% of Insmed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Which has more risk & volatility, RARE or INSM?

Ultragenyx Pharmaceutical has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Is RARE or INSM more profitable?

Ultragenyx Pharmaceutical has a net margin of -139.70% compared to Ultragenyx Pharmaceutical's net margin of -245.59%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-139.70%	-369.54%	-44.74%
Insmed	-245.59%	N/A	-53.34%

Which has higher valuation and earnings, RARE or INSM?

Ultragenyx Pharmaceutical has higher revenue and earnings than Insmed. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$434.25M	8.04	-$606.64M	-$8.33	-5.09
Insmed	$305.21M	11.73	-$749.57M	-$5.34	-4.51

Do analysts recommend RARE or INSM?

Ultragenyx Pharmaceutical currently has a consensus target price of $91.55, indicating a potential upside of 116.06%. Insmed has a consensus target price of $44.64, indicating a potential upside of 84.30%. Given Insmed's higher probable upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Insmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Insmed	0 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community favor RARE or INSM?

Ultragenyx Pharmaceutical received 301 more outperform votes than Insmed when rated by MarketBeat users. Likewise, 77.09% of users gave Ultragenyx Pharmaceutical an outperform vote while only 64.68% of users gave Insmed an outperform vote.

Company	Underperform	Outperform
Ultragenyx Pharmaceutical	Outperform Votes 801 77.09%	Underperform Votes 238 22.91%
Insmed	Outperform Votes 500 64.68%	Underperform Votes 273 35.32%

Does the media prefer RARE or INSM?

In the previous week, Ultragenyx Pharmaceutical had 11 more articles in the media than Insmed. MarketBeat recorded 14 mentions for Ultragenyx Pharmaceutical and 3 mentions for Insmed. Insmed's average media sentiment score of 0.43 beat Ultragenyx Pharmaceutical's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	5 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ultragenyx Pharmaceutical beats Insmed on 11 of the 18 factors compared between the two stocks.